Publication: Cell-main spectra profile screening technique in simulation of circulating tumour cells using maldi-tof mass spectrometry
Issued Date
2021-08-01
Resource Type
ISSN
20726694
Other identifier(s)
2-s2.0-85111113624
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancers. Vol.13, No.15 (2021)
Suggested Citation
Wararat Chiangjong, Sebastian Chakrit Bhakdi, Noppawan Woramongkolchai, Thitinee Vanichapol, Nutkridta Pongsakul, Suradej Hongeng, Somchai Chutipongtanate Cell-main spectra profile screening technique in simulation of circulating tumour cells using maldi-tof mass spectrometry. Cancers. Vol.13, No.15 (2021). doi:10.3390/cancers13153775 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76091
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cell-main spectra profile screening technique in simulation of circulating tumour cells using maldi-tof mass spectrometry
Abstract
Circulating atypical cells (CAC) are released from a primary tumour site into peripheral blood and are indicators of cancer metastasis. CAC occur at very low frequency in circulating blood, and their detection remains challenging. Moreover, white blood cells (WBC) are the major contami-nant in enriched CAC samples. Here, we developed matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as a novel CAC characterization platform. Main spectra profiles (MSP) of normal and cancer cells were generated by MALDI-TOF MS, and a cell-main spectra database was then compiled and analysed using the MALDI Biotyper software. Logarithmic scores accurately predicted distinct cell types. The feasibility of this workflow was then validated using simulated samples, which were prepared by 5000 WBC of three healthy individuals spiked with varying numbers (3, 6, 12, 25, 50, and 100) of lung, colon, or prostate cancer cells. MALDI-TOF MS was able to detect cancer cells down to six cells over the background noise of 5000 WBC with significantly higher predictive scores as compared to WBC alone. Further development of cell-MSP database to cover all cancer types sourced from cell lines and patient tumours may enable the use of MALDI-TOF MS as a cancer-screening platform in clinical settings in the future.